[go: up one dir, main page]

MX2018007074A - Moduladores de canales de kv3 para tratar dolor. - Google Patents

Moduladores de canales de kv3 para tratar dolor.

Info

Publication number
MX2018007074A
MX2018007074A MX2018007074A MX2018007074A MX2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A
Authority
MX
Mexico
Prior art keywords
modulators
channels
treat pain
prophylaxis
pain
Prior art date
Application number
MX2018007074A
Other languages
English (en)
Other versions
MX385578B (es
Inventor
Giuseppe Alvaro
Charles Large
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of MX2018007074A publication Critical patent/MX2018007074A/es
Publication of MX385578B publication Critical patent/MX385578B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona un modulador de canales Kv3.1 y/o Kv3.2 y/o Kv3.3 para su usarse en la profilaxis o el tratamiento del dolor; moduladores para usarse en la profilaxis o el tratamiento del dolor incluyen compuestos de fórmula (I) o una sal y/o solvato farmacéuticamente aceptable de los mismos y/o sus derivados. (ver Fórmula).
MX2018007074A 2015-12-10 2016-12-09 Moduladores de canales de kv3 para tratar dolor. MX385578B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain

Publications (2)

Publication Number Publication Date
MX2018007074A true MX2018007074A (es) 2018-12-12
MX385578B MX385578B (es) 2025-03-18

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007074A MX385578B (es) 2015-12-10 2016-12-09 Moduladores de canales de kv3 para tratar dolor.

Country Status (21)

Country Link
US (3) US11147813B2 (es)
EP (1) EP3386506B1 (es)
JP (3) JP7149847B2 (es)
KR (1) KR102812887B1 (es)
CN (2) CN108472288B (es)
AU (1) AU2016367239B2 (es)
BR (1) BR112018011700B1 (es)
CA (1) CA3005302A1 (es)
DK (1) DK3386506T3 (es)
EA (1) EA038059B1 (es)
ES (1) ES2974902T3 (es)
FI (1) FI3386506T3 (es)
GB (1) GB201521751D0 (es)
HR (1) HRP20240497T1 (es)
HU (1) HUE066879T2 (es)
IL (1) IL259717B (es)
MX (1) MX385578B (es)
PL (1) PL3386506T3 (es)
PT (1) PT3386506T (es)
SG (1) SG11201804123VA (es)
WO (1) WO2017098254A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
US20200039970A1 (en) 2016-12-16 2020-02-06 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
JP7465868B2 (ja) 2018-10-16 2024-04-11 アウトイフオンイ トヘラペウトイクス リミテッド 新規化合物
TW202031645A (zh) * 2018-10-30 2020-09-01 丹麥商Ｈ 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
TWI853857B (zh) 2018-11-30 2024-09-01 日商大塚製藥股份有限公司 雜環化合物
AU2020427632B2 (en) 2020-02-06 2025-12-18 Autifony Therapeutics Limited Kv3 modulators
EP4384504A1 (en) 2021-08-10 2024-06-19 Autifony Therapeutics Limited Potassium channel modulators
CN113788741B (zh) * 2021-09-28 2023-12-29 大连九信精细化工有限公司 一种制备2-环丙基苯酚衍生物的方法
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524344A (ja) 2008-06-06 2011-09-01 ユセベ ファルマ ソシエテ アノニム シクロブトキシ基を含む化合物
BR112012015868A2 (pt) * 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
EA023768B1 (ru) * 2010-12-06 2016-07-29 Отифони Терапеутикс Лимитед ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
JP6008953B2 (ja) 2011-06-07 2016-10-19 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
AU2012349847B2 (en) * 2011-12-06 2017-02-16 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9422252B2 (en) * 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
BR112018011700A2 (pt) 2018-11-27
SG11201804123VA (en) 2018-06-28
KR102812887B1 (ko) 2025-05-26
ES2974902T3 (es) 2024-07-02
EP3386506B1 (en) 2024-01-24
IL259717B (en) 2021-05-31
EP3386506A1 (en) 2018-10-17
DK3386506T3 (da) 2024-05-06
EA201891377A1 (ru) 2019-01-31
BR112018011700B1 (pt) 2023-12-26
HRP20240497T1 (hr) 2024-08-16
JP2019506367A (ja) 2019-03-07
IL259717A (en) 2018-07-31
CN118267386A (zh) 2024-07-02
HUE066879T2 (hu) 2024-09-28
PL3386506T3 (pl) 2024-06-03
PT3386506T (pt) 2024-03-28
MX385578B (es) 2025-03-18
US20220071998A1 (en) 2022-03-10
JP7149847B2 (ja) 2022-10-07
KR20180097549A (ko) 2018-08-31
AU2016367239B2 (en) 2020-07-09
US20250017925A1 (en) 2025-01-16
WO2017098254A1 (en) 2017-06-15
AU2016367239A1 (en) 2018-06-07
US11944623B2 (en) 2024-04-02
CN108472288B (zh) 2024-05-28
GB201521751D0 (en) 2016-01-27
FI3386506T3 (fi) 2024-04-23
JP2025003958A (ja) 2025-01-14
US11147813B2 (en) 2021-10-19
EA038059B1 (ru) 2021-06-30
CN108472288A (zh) 2018-08-31
CA3005302A1 (en) 2017-06-15
US20190000848A1 (en) 2019-01-03
JP2022141699A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
ECSP20003147A (es) Carboxamidas como moduladores de los canales de sodio
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
ECSP19083923A (es) Inhibidores pirazólicos de magl
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
SV2018005708A (es) Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje
MX2019014024A (es) Tratamiento de los trastornos depresivos.
MX2022006862A (es) Inhibidores duales de magl y faah.
MX388722B (es) Compuestos para tratar el cancer de ovario.
SV2016005313A (es) Derivados de carboxamida
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CO2019002517A2 (es) Inhibidores de dopamina–β–hidroxilasa
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY36123A (es) Derivados de carboxamida
CL2019001406A1 (es) Moduladores de ror gamma (rory).
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
CU20160170A7 (es) Derivados de carboxamida